bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.06.10.731436

First Genome-Scale Metabolic Model for Understanding HMPV-Host Interaction

Hussain, S.·Beierle, L.·Schmeck, B.·Mostolizadeh, R.
View original source ↗Export metadata ↓

Abstract

BackgroundHuman Metapneumovirus (HMPV) is a major contributor to acute respiratory tract infections. Currently, no approved vaccines or specific antiviral therapies are available worldwide. Genome-scale metabolic models (GEMs), when integrated with Viral Biomass Objective Functions (VBOFs), provide a robust computational framework for identifying host metabolic dependencies essential for viral replication. This approach enables systematic prioritization of potential antiviral drug targets. ResultsThe first comprehensive VBOF for HMPV was constructed by integrating stoichiometric data from the viral genome, including structural proteins with defined copy numbers, amino acid residues per virion, envelope lipids, and glycan modifications. The reconstructed VBOF was incorporated into the human bronchial epithelial cell model, iHBEC1, to analyze metabolic changes between uninfected and infected host cells. Knockout analysis identified two selective antiviral gene targets: PGM3 (phosphoacetylglucosamine mutase) and GNPNAT1 (N-acetylglucosamine-6-phosphate acetyltransferase), as well as seven selective reaction targets primarily within the hexosamine biosynthesis and nucleotide sugar pathways. Knockout of PGM3 or GNPNAT1 completely abolished viral production while preserving complete host cell viability. Additionally, guanylate kinase (GUK1/GK1) emerged as a highly selective target for HMPV, confirming findings from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) studies and suggesting a conserved vulnerability across respiratory viruses. ConclusionsUDP-GlcNAc, the vital end-product of the hexosamine biosynthesis pathway (HBP), is computationally predicted as a critical metabolic hub. This pathway represents the primary metabolic vulnerability of HMPV, due to the extensive glycosylation requirements of the HMPV attachment protein. The host-directed antiviral targets PGM3 and GNPNAT1 are high-priority candidates for experimental validation and may provide novel strategies to combat this respiratory infection.

Explore related subjects

Systems BiologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hussain, S., Beierle, L., Schmeck, B., Mostolizadeh, R.. 2026-06-14. First Genome-Scale Metabolic Model for Understanding HMPV-Host Interaction. https://doi.org/10.64898/2026.06.10.731436

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Personalized Immunotherapy via Multiscale Tumor-Immune Modeling and Optimal Control

Cancer remains a global health challenge requiring sophisticated understanding of tumor-immune dynamics for effective treatment design. Mathematical oncology has emerged as a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. This paper presents a comprehensive multiscale framework integrating patient-specific data, machine learning, and optimal control for personalized immunotherapy design. We develop a hybrid model that combines deterministic dynamics with stochastic elements and time delays, capturing the inherent variability and temporal lags in biological processes. The model incorporates biologically realistic Holling Type-II functional responses and is validated against longitudinal clinical data from 100+ cancer patients and patient-derived organoid experiments. Using deep neural networks with Bayesian regularization, we learn patient-specific parameter distributions from clinical biomarkers and predict treatment responses with high accuracy. Our optimal control framework, incorporating clinical constraints and toxicity limits, generates personalized treatment protocols that stabilize otherwise unstable dynamics. The framework establishes a new paradigm for precision immuno-oncology, bridging mathematical theory, computational methods, and clinical practice. Author summaryCancer remains one of the leading causes of death worldwide, and the immune system plays a crucial role in controlling tumor growth. However, the complex interactions between tumor cells and immune cells make it difficult to predict how individual patients will respond to immunotherapy. In this work, we develop a mathematical framework that integrates patient-specific data, machine learning, and optimal control to design personalized immunotherapy strategies. Our model captures the realistic dynamics of tumor-immune interactions by incorporating biologically relevant features such as time delays (representing immune response lags) and stochastic effects (representing biological variability). Using deep learning, we estimate patient-specific parameters from clinical biomarkers, enabling personalized predictions of treatment outcomes. We validate our framework against data from over 100 cancer patients and patient-derived organoid experiments, demonstrating excellent agreement. Our optimal control approach generates personalized treatment protocols that stabilize otherwise unstable tumor dynamics, achieving 78% tumor reduction compared to 52% for standard-of-care protocols. These findings suggest that therapies targeting immunological thresholds may be as important as those directly killing tumor cells, providing a new perspective for immunotherapy design. This framework bridges mathematical theory, computational methods, and clinical practice, offering a pathway toward truly personalized cancer treatment.

Systems Biology↗
bioRxiv2026

Reversible Opto-Chemical activation of KRASG12V signaling with near single-cell precision

KRAS mutations drive some of the most lethal carcinomas, and genomic and inducible systems have established many of the cellular and tissue-level consequences. However, these approaches operate at the level of oncogene expression, allowing for cellular adaptation that masks the individual role of KRAS oncoprotein signaling. Here, we developed a reversible Opto-Chemical system to activate KRAS signaling by chemically translocating a cytosolic mutant KRASG12V G-domain to the plasma membrane upon light or small-molecule input. In MDCK cells, the G-domain plasma membrane recruitment activated downstream signaling and reduced collective migration. In mouse small Intestinal Organoids, G-domain recruitment promoted increased crypt size and number under Epidermal Growth Factor-deprived conditions. We further showed that the increased number of crypts depended on continuous KRASG12V signaling. Finally, under the same deprived conditions, localized activation in just one budding crypt promoted crypt formation compared to controls. This system decouples oncoprotein activity from oncogene expression, allowing to investigate the KRAS signaling contribution to early epithelial transformation.

Systems Biology↗
bioRxiv2026

Mammalian aging involves genome-wide splicing degeneration leading to functional decline

Alternative splicing exhibits significant changes during development and aging, affecting the composition and variance in the transcriptome. However, it is unclear whether and how age-associated splicing dysregulation leads to functional consequences. Here, an integrative analysis of transcriptome data across mouse and human tissues revealed that aging is characterized by systematic deterioration of the fidelity of RNA splicing, here termed splicing degeneration, a measure of functional alteration of reading frame and domain configuration of protein products. Genes with higher aging-associated splicing degeneration were more conserved and enriched for processes such as RNA metabolism and antigen presentation. By assessing alternative splicing events associated with functional deterioration, we quantified the degree of splicing degeneration. Its level increased with age but was alleviated following calorie restriction or rapamycin treatment, indicating that it can serve as a new molecular hallmark of aging. Mechanistically, through a comprehensive meta-data analysis, we discovered that splicing degeneration is associated with age-associated changes in specific splicing factors, which in turn showed a strong association with age-related transcriptome changes. Overall, our study demonstrates the intricate relationship between aging and genome-wide splicing degeneration, revealing a promising target for aging interventions acting to reverse splicing degeneration.

Systems Biology↗